secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vor Biopharma Inc. (VOR)
CIK:        0001817229
Form:       8-K
Filed at:   2026-06-08T20:01:29+00:00
Accession:  0001193125-26-261661
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

RemeGen gets NMPA nods for telitacicept in IgAN and Sjögren’s; Vor Bio holds ex-China rights
--------------------------------------------------------------------------------

- First BAFF/APRIL-targeting therapy approved for IgA nephropathy; conditional NMPA approval based on Phase 3 TELIGAN trial showing 55% placebo-adjusted UPCR reduction.
- First regulatory approval ever for Sjögren’s disease in China; Phase 3 met primary and secondary endpoints (ESSDAI, ESSPRI).
- Telitacicept now has five approved indications in China; Vor Bio holds exclusive development/commercialization rights outside Greater China.
- Phase 3 IgAN results recently published in NEJM; eGFR stable at 39 weeks vs declines on placebo.
- Vor Bio CEO cites milestone validating dual BAFF/APRIL inhibition as potential foundational therapy for autoimmune diseases.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1817229/000119312526261661/0001193125-26-261661-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1817229/000119312526261661/vor-20260608.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-261661

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer